ABSI Absci
Generative-AI antibody design
Fundamentals from public market data, refreshed daily (2026-10-30 21:21 UTC). Figures in reporting currency.
ABSI · price with what management and the data said
Timeline: management commentary, data & earnings
8 events-
8
2026-08-11EarningsMiss / cut
Reported EPS -0.21 vs -0.2 expected (-6.4% surprise).
-
7
2026-05-07EarningsBeat / raise
Reported EPS -0.19 vs -0.2 expected (+4.6% surprise).
-
6
2026-03-24EarningsMiss / cut
Reported EPS -0.23 vs -0.17 expected (-32.5% surprise).
-
5
2025-11-12EarningsBeat / raise
Reported EPS -0.2 vs -0.21 expected (+2.5% surprise).
-
4
2025-08-12EarningsMiss / cut
Reported EPS -0.24 vs -0.21 expected (-15.1% surprise).
-
3
2025-05-13EarningsBeat / raise
Reported EPS -0.21 vs -0.22 expected (+6.0% surprise).
-
2
2025-03-18EarningsMiss / cut
Reported EPS -0.25 vs -0.22 expected (-11.7% surprise).
-
1
2024-11-12EarningsMiss / cut
Reported EPS -0.24 vs -0.19 expected (-23.1% surprise).
Latest headlines
Auto-updated daily- Absci Sinks 8%, Schrödinger and Recursion Slide as AI Drug Discovery Stocks Give Back Rally2026-10-30
- Does Positive Hair Loss Trial Data Change The Bull Case For Absci Stock?2026-10-30
- Absci Soars 12%, Schrödinger Up 11%, Recursion Up 9% as AI Drug Discovery Stocks Rally2026-10-28
- Absci to Participate in Upcoming Investor Conferences2026-10-27
- Is Absci (ABSI) Undervalued As Positive ABS 201 Phase 1 Data Lifts Optimism?2026-10-24
- Absci (ABSI) Stock Seems Rich Against Its Book Value Backdrop2026-10-16
- Absci to Report Business Updates and Third Quarter 2026 Financial and Operating Results on November 12, 20262026-10-13
Earnings history
EPS vs expectations| Date | Expected EPS | Reported EPS | Surprise |
|---|---|---|---|
| 2026-08-11 | -0.2 | -0.21 | −6.4% |
| 2026-05-07 | -0.2 | -0.19 | +4.6% |
| 2026-03-24 | -0.17 | -0.23 | −32.5% |
| 2025-11-12 | -0.21 | -0.2 | +2.5% |
| 2025-08-12 | -0.21 | -0.24 | −15.1% |
| 2025-05-13 | -0.22 | -0.21 | +6.0% |
| 2025-03-18 | -0.22 | -0.25 | −11.7% |
| 2024-11-12 | -0.19 | -0.24 | −23.1% |
| 2024-08-14 | -0.18 | -0.22 | −20.0% |
| 2024-05-14 | -0.2 | -0.22 | −11.9% |
| 2024-03-21 | -0.22 | -0.25 | −12.6% |
| 2023-11-14 | -0.22 | -0.24 | −7.5% |
| 2023-08-14 | -0.24 | -0.22 | +6.7% |
| 2023-05-15 | -0.24 | -0.26 | −9.5% |
| 2023-03-30 | -0.25 | -0.21 | +15.3% |
| 2022-11-09 | -0.28 | -0.3 | −7.8% |
| 2022-08-11 | -0.31 | -0.32 | −4.6% |
| 2022-05-11 | -0.28 | -0.33 | −17.0% |
| 2022-03-22 | -0.24 | -0.28 | −16.7% |
| 2021-11-09 | -0.17 | -0.33 | −94.1% |
| 2021-09-07 | -0.87 | -0.75 | +13.7% |
About Absci
Website ↗Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Models now design molecules and antibodies, but clinical trials are still the gate. Value accrues to platforms with wet-lab data and pharma partnerships.
What would prove us wrong. Weakens if AI-designed candidates fail in the clinic at rates no better than traditional discovery.
Who else supplies this
| Stock | Role | Last | 1D | 1M | YTD | Trend |
|---|---|---|---|---|---|---|
| RXRX Recursion Pharmaceuticals | AI drug discovery with NVIDIA-backed compute | $4.03 | −4.95% | −1.0% | −1.5% | |
| SDGR Schrödinger | Physics-plus-AI molecular design software | $27.14 | −9.50% | −10.9% | +51.8% | |
| ABCL AbCellera Biologics | AI-driven antibody discovery | $12.27 | −6.19% | −11.8% | +258.8% | |
| TEM Tempus AI | Clinical and genomic data for AI diagnostics | $72.22 | −7.22% | −5.6% | +22.3% |
Not investment advice. Prices delayed and in local currency. Quotes in "double quotes" are verbatim as reported by the linked source; other commentary is our paraphrase. Earnings dates are estimates.